Geodesic
A Cost-Effectiveness-Assessing Model of Vaccination for Varicella and Zoster
M. Comba1 ; S. Martorano-Raimundo2 ; E. Venturino1
1 Dipartimento di Matematica “Giuseppe Peano”, via Carlo Alberto 10, Università di Torino, 10123 Torino, Italia
2 Faculdade de Medicina, Universidade de São Paulo, Instituto Oscar Freire, CEP : 05405-000, Rua Teodoro Sampaio, 115, São Paulo, S.P., Brazil
Mathematical modelling of natural phenomena, Tome 7 (2012) no. 3, pp. 62-77

Voir la notice de l'article provenant de la source EDP Sciences

A decision analytical model is presented and analysed to assess the effectiveness and cost-effectiveness of routine vaccination against varicella and herpes-zoster, or shingles. These diseases have as common aetiological agent the varicella-zoster virus (VZV). Zoster can more likely occur in aged people with declining cell-mediated immunity. The general concern is that universal varicella vaccination might lead to more cases of zoster: with more vaccinated children exposure of the general population to varicella infectives become smaller and thus a larger proportion of older people will have weaker immunity to VZV, leading to more cases of reactivation of zoster. Our compartment model shows that only two possible equilibria exist, one without varicella and the other one where varicella and zoster both thrive. Threshold quantities to distinguish these cases are derived. Cost estimates on a possible herd vaccination program are discussed indicating a possible tradeoff choice.
DOI : 10.1051/mmnp/20127306

M. Comba 1 ; S. Martorano-Raimundo 2 ; E. Venturino 1

1 Dipartimento di Matematica “Giuseppe Peano”, via Carlo Alberto 10, Università di Torino, 10123 Torino, Italia
2 Faculdade de Medicina, Universidade de São Paulo, Instituto Oscar Freire, CEP : 05405-000, Rua Teodoro Sampaio, 115, São Paulo, S.P., Brazil 
@article{10_1051_mmnp_20127306,
     author = {M. Comba and S. Martorano-Raimundo and E. Venturino},
     title = {A {Cost-Effectiveness-Assessing} {Model} of {Vaccination} for {Varicella} and {Zoster}},
     journal = {Mathematical modelling of natural phenomena},
     pages = {62--77},
     publisher = {mathdoc},
     volume = {7},
     number = {3},
     year = {2012},
     doi = {10.1051/mmnp/20127306},
     language = {en},
     url = {http://geodesic.mathdoc.fr/articles/10.1051/mmnp/20127306/}
}
TY  - JOUR
AU  - M. Comba
AU  - S. Martorano-Raimundo
AU  - E. Venturino
TI  - A Cost-Effectiveness-Assessing Model of Vaccination for Varicella and Zoster
JO  - Mathematical modelling of natural phenomena
PY  - 2012
SP  - 62
EP  - 77
VL  - 7
IS  - 3
PB  - mathdoc
UR  - http://geodesic.mathdoc.fr/articles/10.1051/mmnp/20127306/
DO  - 10.1051/mmnp/20127306
LA  - en
ID  - 10_1051_mmnp_20127306
ER  - 
%0 Journal Article
%A M. Comba
%A S. Martorano-Raimundo
%A E. Venturino
%T A Cost-Effectiveness-Assessing Model of Vaccination for Varicella and Zoster
%J Mathematical modelling of natural phenomena
%D 2012
%P 62-77
%V 7
%N 3
%I mathdoc
%U http://geodesic.mathdoc.fr/articles/10.1051/mmnp/20127306/
%R 10.1051/mmnp/20127306
%G en
%F 10_1051_mmnp_20127306
M. Comba; S. Martorano-Raimundo; E. Venturino. A Cost-Effectiveness-Assessing Model of Vaccination for Varicella and Zoster. Mathematical modelling of natural phenomena, Tome 7 (2012) no. 3, pp. 62-77. doi: 10.1051/mmnp/20127306

[1] A. M. Arvin, A. A. Gershon Ann. Rev. Microbiol. 1996 59 100

[2] A. M. Arvin, A. A. Gershon Ann Rev Microbiol. 1996 59 100

[3] M. Brisson, W. J. Edmunds, N. J. Gay, B. Law, G. De Serres Epidemiology and Infection 2000 651 669

[4] CDC. Prevention of varicella : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 56 (2007), No. RR4, OpenURL.

[5] Centers for Disease Control and Prevention. Prevention of varicella : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 45 (1997), No. RR-11, 35–40.

[6] S. Deguen, A. Flahault European Journal of Epidemiology 2000 1177 1181

[7] O. Diekmann, J. A. P. Heesterbeek, J. A. J. Metz Journal of Mathematical Biology 1990 365 382

[8] W. J. Edmunds, M. Brisson Journal of Infection 2002 211 219

[9] J. E. Forde, B. Meeker Mathematical Biosciences and Engineering 2010 765 777

[10] G. P. Garnett, N. M. Ferguson Rev. Med. Virol. 1996 151 161

[11] G. P. Garnett, B. T. Grenfell Epidemiology and Infection 1992 513 528

[12] S. Hambleton, S. P. Steinberg, P. S. La Russa, E. D. Shapiro, A. A. Gershon J. Infect. Dis. 2008 S196 199

[13] R. E. Hope-Simpson Proc. Roy. Soc. Med. 1965 9 20

[14] J. Hornberger, K. Robertus Ann Intern Med. 2006 317 325

[15] M. Karhunen, T. Leino, H. Salo, I. Davidkin, T. Kilpi, K. Auranen Epidemiol Infect. 2010 469 481

[16] M. N. Oxman, M. J. Levin, G. R. Johnson, K. E. Schmader, S. E. Straus, L. D. Gelb, R. D. Arbeit, M. S. Simberkoff, A. A. Gershon, L. E. Davis, A. Weinberg, K. D. Boardman, H. M. Williams, J. Hongyuan Zhang, P. N. Peduzzi, C. E. Beisel, V. A. Morrison, J. C. Guatelli, P. A. Brooks, C. A. Kauffman, C. T. Pachucki, K. M. Neuzil, R. F. Betts, P. F. Wright, M. R. Griffin, P. Brunell, N. E. Soto, A. R. Marques, S. K. Keay, R. P. Goodman, D. J. Cotton, J. W. Gnann, J. Loutit, M. Holodniy, W. A. Keitel, G. E. Crawford, S.-S. Yeh, Z. Lobo, J. F. Toney, R. N. Greenberg, P. M. Keller, R. Harbecke, A. R. Hayward, M. R. Irwin, T. C. Kyriakides, C. Y. Chan, I. S. F. Chan, W. W. B. Wang, P. W. Annunziato, J. L. Silber N. Engl. J. Med. 2005 2271 2284

[17] M. N. Oxman, M.J. Levin J Infect Dis. 2008 S228 5236

[18] M. Socan, N. Berginc, J. Lajovic BMC Public Health 2010 1 6

[19] M. C. Schuette, H. W. Hethcote Bull Math Biol. 1999 1031 1064

[20] G. Soldato. Nuove strategie preventive vaccinali : vantaggi e limiti del vaccino antivaricella (New preventive vaccine strategies : advantages and limits of the vaccine against chickenpox). Thesis (Advisor Prof. C. Granchelli), University “G. D’Annunzio” of Chieti-Pescara, Italy, 2005.

[21] N. Thiry, P. Beutels, F. Tancredi, L. Romanò, A. Zanetti, P. Bonanni, G. Gabutti, P. Van Damme Vaccine 22 2004 3546 3562

[22] A. J. Van Hoek, N. Gay, W. Opstelten, W. J. Edmunds Vaccine 2009 1454 1467

[23] A. J. Van Hoek, A. Melegaro, E. W. Zaghenid, J. Edmunds, N. Gay Vaccine 2011 2411 2420

[24] M. Wharton Infect Dis Clinics N Am 1996 571 581

Cité par Sources :